Bicycle Therapeutics plc (NASDAQ:BCYC) reported Q4 EPS of ($1.01), $0.05 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $3.55 million.
Bicycle Therapeutics plc (NASDAQ:BCYC) reported Q4 EPS of ($1.01), $0.05 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $3.55 million.